Works matching IS 11707690 AND DT 2024 AND VI 42 AND IP 2

Results: 8

Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study.

Published in:

PharmacoEconomics, 2024, v. 42, n. 2, p. 219, doi. 10.1007/s40273-023-01326-y

By:

Mar, Javier;
Ibarrondo, Oliver;
Estadilla, Carlo Delfin S.;
Stollenwerk, Nico;
Antoñanzas, Fernando;
Blasco-Aguado, Rubén;
Larrañaga, Igor;
Bidaurrazaga, Joseba;
Aguiar, Maíra

Publication type:

Article

Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.

Published in:

PharmacoEconomics, 2024, v. 42, n. 2, p. 231, doi. 10.1007/s40273-023-01322-2

By:

Yee, Christopher W.;
Harvey, Michael J.;
Xin, Yiqiao;
Kirson, Noam Y.

Publication type:

Article

A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects.

Published in:

PharmacoEconomics, 2024, v. 42, n. 2, p. 199, doi. 10.1007/s40273-023-01331-1

By:

Lamsal, Ramesh;
Yeh, E. Ann;
Pullenayegum, Eleanor;
Ungar, Wendy J.

Publication type:

Article

Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum.

Published in:

PharmacoEconomics, 2024, v. 42, n. 2, p. 137, doi. 10.1007/s40273-023-01334-y

By:

Gladwell, Daniel;
Ciani, Oriana;
Parnaby, Adam;
Palmer, Stephen

Publication type:

Article

Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments.

Published in:

PharmacoEconomics, 2024, v. 42, n. 2, p. 165, doi. 10.1007/s40273-023-01323-1

By:

Turner, Alex J.;
Sammon, Cormac;
Latimer, Nick;
Adamson, Blythe;
Beal, Brennan;
Subbiah, Vivek;
Abrams, Keith R.;
Ray, Joshua

Publication type:

Article

Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective.

Published in:

PharmacoEconomics, 2024, v. 42, n. 2, p. 133, doi. 10.1007/s40273-023-01328-w

By:

Orozco-Leal, Giovany;
Johnson, Eugenie Evelynne;
Hosseinijebeli, Sedighe;
Robinson, Tomos;
Homer, Tara;
Eastaugh, Claire H.;
Richmond, Catherine;
Tanner, Louise;
Meader, Nick;
Kenny, Ryan;
Wallace, Sheila A.;
Rice, Stephen

Publication type:

Article

Systematic Review of the Relative Social Value of Child and Adult Health.

Published in:

PharmacoEconomics, 2024, v. 42, n. 2, p. 177, doi. 10.1007/s40273-023-01327-x

By:

Peasgood, Tessa;
Howell, Martin;
Raghunandan, Rakhee;
Salisbury, Amber;
Sellars, Marcus;
Chen, Gang;
Coast, Joanna;
Craig, Jonathan C.;
Devlin, Nancy J.;
Howard, Kirsten;
Lancsar, Emily;
Petrou, Stavros;
Ratcliffe, Julie;
Viney, Rosalie;
Wong, Germaine;
Norman, Richard;
Donaldson, Cam

Publication type:

Article

A Framework for the Fair Pricing of Medicines.

Published in:

PharmacoEconomics, 2024, v. 42, n. 2, p. 145, doi. 10.1007/s40273-023-01325-z

By:

Paulden, Mike

Publication type:

Article